Medindia

X

Poniard Pharmaceuticals Announces Upcoming Conference Participation

Wednesday, August 27, 2008 General News J E 4
Advertisement
SOUTH SAN FRANCISCO, Calif., Aug. 27 PoniardPharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused ononcology, today announced that Jerry McMahon, Ph.D., chairman and CEO, willparticipate in three upcoming conferences in September during which he willprovide a corporate overview, including a discussion of the clinicaldevelopment program for picoplatin, the Company's lead product candidate.

-- The Thomas Weisel Partners Healthcare Conference on Wednesday,September 3, at 4:25 p.m. Eastern Time at the Four Seasons Hotel in Boston

-- BioCentury's NewsMakers in the Biotech Industry Conference on Thursday,September 4, at 2:30 p.m. Eastern Time at the Millennium Broadway Hotel in NewYork

-- The 3rd Annual Citi Biotech Day on Monday, September 8, at 2:35 p.m.Eastern Time at the Citi Center in New York

Live audio webcasts of Poniard's presentations at the Thomas WeiselPartners Healthcare Conference and Citi Biotech Day will be available for 10business days following each conference. Each webcast can be accessed on the"Events" page of the "News & Events" section of the Company's website athttp://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused onthe development and commercialization of innovative oncology products toimpact the lives of people with cancer. Picoplatin, the Company's leadplatform product candidate, is a new generation platinum therapy with animproved safety profile relative to existing platinum-based cancer therapies.Picoplatin is designed to overcome platinum resistance associated withchemotherapy in solid tumors, and is being studied in multiple cancerindications, combinations and formulations. Clinical trials of intravenouspicoplatin include a Phase 3 trial in small cell lung cancer and Phase 2trials in metastatic colorectal and hormone-refractory prostate cancers, aswell as a clinical trial of oral picoplatin in solid tumors. Picoplatin hasnot been approved by any regulatory authority for use in humans. Foradditional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of PoniardPharmaceuticals, Inc.

SOURCE Poniard Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Award-Winning Healthcare Policy Researcher Keynote...
S
Varian, Inc. to Present at Thomas Weisel Partners'...